Einloggen
E-Mail
Passwort
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

GILEAD SCIENCES, INC.

(885823)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über GILEAD SCIENCES, INC.
16:37GILEAD SCIENCES : Endows Its Foundation With More Than $200 Million to Support H..
13:21BIONTECH : Completes Cell Therapy Platform, Facility Purchase From Gilead Unit
13:00PRESS RELEASE : BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell The..
03.08.Assembly Biosciences Names New COO, CFO
03.08.GILEAD SCIENCES : Endows Its Foundation With More Than $200 Million to Support H..
30.07.SECTOR UPDATE : Health Care Stocks Scratching Out Small Advance Just Ahead of Fr..
30.07.GLOBAL MARKETS LIVE : Caterpillar, Chevron, Robinhood, Bayer, Gilead Sciences...
30.07.Résumé des principales informations économiques du vendredi 30 juillet 2021
30.07.Hoy en Wall Street: Sin preocuparse por el mundo
30.07.Today on Wall Street: Without a care in the world
30.07.ANALYST RECOMMENDATIONS : Amazon, Barclays, Comcast, Next, Pfizer...
30.07.Como una carta por correo
30.07.AVIS D'ANALYSTES DU JOUR : Air Liquide, Airbus, TotalEnergies,Vivendi, Nestlé, V..
30.07.EN DIRECT DES MARCHES : Iliad, L'Oréal, Saint-Gobain, Renault, BNP Paribas, Schn..
30.07.Gilead a vendu pour 829 millions de son médicament anti-Covid
29.07.IGM BIOSCIENCES : Names New Chief Medical Officer
29.07.GILEAD SCIENCES : View Second Quarter 2021 Prepared Remarks
29.07.GILEAD SCIENCES : ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS (Form 8-K)
29.07.GILEAD SCIENCES : View Second Quarter 2021 Summary of Remarks
29.07.Gilead Sciences Raises Fiscal Year Product Sales Forecast
29.07.GILEAD SCIENCES : COVID-19 drug helps boost 2nd-quarter results as HIV sales dip
29.07.Gilead sciences says no longer pursuing development of inhaled remdesivir for..
29.07.Gilead Sciences Swings to 2Q Profit as Revenue Soars 21%
29.07.GILEAD SCIENCES : Posts Q2 Gains Above Estimates, Narrows Annual Guidance Range
29.07.GILEAD : Q2 Earnings Snapshot
29.07.GILEAD SCIENCES : View Second Quarter 2021 Earnings Release
29.07.GILEAD SCIENCES : View Second Quarter 2021 Earnings Slides
29.07.GILEAD SCIENCES : View Second Quarter 2021 Supplementary Info
29.07.GILEAD SCIENCES INC : Results of Operations and Financial Condition, Financial S..
29.07.GILEAD SCIENCES : Earnings Flash (GILD) GILEAD SCIENCES Reports Q2 EPS $1.87, vs..
29.07.GILEAD SCIENCES : Earnings Flash (GILD) GILEAD SCIENCES Reports Q2 Revenue $6.22..
29.07.GUIDANCE : (GILD) GILEAD SCIENCES Sees Fiscal Year 2021 EPS Range $6.90 - $7.25
29.07.GILEAD SCIENCES : Announces Second Quarter 2021 Financial Results
29.07.Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter Ended J..
29.07.Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2021
29.07.Gilead Sciences, Inc. Declares Dividend for the Third Quarter of 2021, Payabl..
29.07.EARNINGS REACTION HISTORY : Gilead Sciences, 40.0% Follow-Through Indicator, 2.7..
29.07.Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on Fe..
29.07.Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on Fe..
27.07.INSIDER TRENDS : Insider at Gilead Sciences Acquires Stock Via Option/Derivative..
27.07.Agenda FRANCE & INTERNATIONAL À 7 JOURS
26.07.Farmacéutica japonesa entra en carrera por medicamento oral para Covid-19
21.07.GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
20.07.BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
20.07.ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
20.07.PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
19.07.ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
19.07.Health Care Down Amid Defensive Bias -- Health Care Roundup
19.07.GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
19.07.GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
19.07.GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
19.07.BIONTECH : to Buy Neoantigen TCR Cell Therapy Platform, Facility from Gilead's K..
19.07.BioNTech strengthens cancer therapy expertise with U.S. acquisition
19.07.PRESS RELEASE : BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platf..
19.07.EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
17.07.GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
17.07.GILEAD SCIENCES : Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate Hig..
17.07.Gilead Sciences, Inc Announces Four-Year Biktarvy® Data Presented At Ias 2021..
17.07.Gilead Sciences, Inc Announces New Results from the Ongoing Phase 2/3 CAPELLA..
15.07.GILEAD SCIENCES : to Release Second Quarter 2021 Financial Results on Thursday, ..
13.07.GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
12.07.GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
07.07.COUNTRYSIDE PROPERTIES : UK's Countryside to focus solely on Partnerships busine..
05.07.READY, SET, GO : Crystalize Your Thinking
02.07.GILEAD SCIENCES : Response to Open Letter Regarding Access to AmBisome® (liposom..
29.06.GILEAD SCIENCES : Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free..
29.06.EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
29.06.FS DEVELOPMENT II : Blank-Check Firm FS Development II to Merge With Pardes Bios..
29.06.BERGENBIO : COVID-19 Drug Cuts Death In Mid-Stage Studies
29.06.Pardes Biosciences, Inc. announced that it expects to receive $75 million in ..
28.06.GILEAD SCIENCES : Seeks FDA Nod for Lenacapavir for HIV-1 Patients
28.06.GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
28.06.Gilead Sciences, Inc. Submits New Drug Application to U.S. Food and Drug Admi..
28.06.GILEAD SCIENCES' : Kite Arm Says Yescarta Improves Event-Free Survival by 60% in..
28.06.Gilead Submits NDA for Lenacapavir to U.S. FDA
1  2  3  4  5  6  7  8  9  10Weiter
Offizielle Publikationen
15.06.Bericht 
10.06.Bericht 
12.05.SEC Filing 8K 
12.05.Bericht 
06.05.Bericht 
06.05.SEC Filing 10Q-1 
Anstehende Termine für GILEAD SCIENCES, INC.